Simple blood tests could spot liver cancer earlier in diabetics
NCT ID NCT07675187
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a standard-care group. The goal is to see if the surveillance strategy leads to smaller tumors at diagnosis and better treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GAAD score-based surveillance (blood tests for AFP, PIVKA-II, and liver function)
What this could lead to
If successful, this could establish a simple blood-test strategy to catch liver cancer earlier in people with type 2 diabetes, potentially improving treatment options and survival.
What could go wrong
This is a single-center trial in Taiwan, so results may not apply globally. The surveillance approach may not significantly improve detection or outcomes compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••